Tagged with Obesity

Mexico In recent decades, Mexico has gained notoriety as one of the countries most heavily afflicted by the global epidemic of obesity. Ranking second only to the United States in terms of prevalence, a full two-thirds of the adult Mexican population are nowadays classified as overweight or obese. “This is a…

Denmark As tensions rise over US-EU trade, will the weight-loss drug Ozempic become an unexpected bargaining chip? Stan Jackson explores the risks of leveraging GLP-1s in economic negotiations.   You can always tell when a blockbuster drug has entered the cultural zeitgeist. It’s around the time you start to hear the…

Mexico Karla Alcazar, Head of LATAM at Eli Lilly, discusses the company’s plans to tackle pressing regional health challenges such as obesity, diabetes, and cancer, while also highlighting the region’s critical role in Lilly’s global strategy. Alcazar offers insights into the company’s focus on innovation, diversity, and patient-centricity, as well as…

Global With the emergence of GLP-1 RA therapies the obesity drug market has taken off and stands to be worth some USD 125.3 billion by 2033. Eli Lilly and Novo Nordisk may lead the charge, but other contenders are looking to get a piece of this lucrative market as the two…

Switzerland Anne Mette Wiis Vogelsang, CVP & General Manager of Novo Nordisk Switzerland, discusses Switzerland’s progressive healthcare landscape while addressing key issues like diabetes care, obesity, and systemic healthcare challenges. Vogelsang also calls for increased prioritization of a holistic approach to health, highlighting the importance of primary and secondary prevention, early…

Mexico Valney Suzuki highlights his focus on expanding access to Novo Nordisk’s innovations in Mexico, especially for vulnerable populations; the importance of ethical usage of the company’s groundbreaking semaglutide-based treatments for diabetes and obesity; and Mexico’s crucial role in Novo Nordisk’s global operations, not just as a market but also in…

Saudi Arabia Noncommunicable diseases are the leading cause of death and disability worldwide, accounting for 74 percent of all deaths and more than three out of four years lived with a disability. These chronic conditions – which cannot be transmitted from person to person and often require long-term or lifelong care –…

India India faces a significant diabetes burden, with some observers even labelling the country ‘The Diabetes Capital of the World’. Around 101.4 million adults, or 11 percent of the Indian population, have diabetes.   As Dr Brij Mohan, president of India’s Diabetes & Obesity Centre surmises, Indians tend to develop diabetes…

Saudi Arabia With over 40 years of history in Saudi Arabia, in 2021 Eli Lilly moved to establish a regional headquarters in the country, underscoring its dedication to the country and region. Now led by Brazilian national Felipe Borges dos Reis, Lilly aims to tackle the pressing health concerns of diabetes and…

India President of India’s Diabetes & Obesity Centre, Dr Brij Mohan has an extensive background in the field of diabetes, having served on the board of Diabetes India and as president of the Research Society for the Study of Diabetes in India (RSSDI). He outlines the significant diabetes burden in a…

Portugal Diabetes is a rising threat to the Portuguese people, the country’s healthcare system, and its economy. Portugal’s National Diabetes Observatory observed that 1.1 million Portuguese people between the ages of 20 and 79.5 (out of a total population of just 10.3 million) were living with diabetes in 2021.   This…

Portugal Novo Nordisk’s spectacular ascendancy in 2023 has meant that its country managers across the world have had to embrace scrutiny and press coverage like never before.   In its centenary year, the Danish firm’s new generation of obesity drugs supercharged revenues to around EUR 30 billion, a 30 percent hike…